Write in a clean editor, then format for Antibody Therapeutics in one click — DocuGuru applies the official Oxford University Press template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Antibody Therapeutics is a peer-reviewed journal published by Oxford University Press, covering Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Protein purification and stability.
| Publisher | Oxford University Press |
|---|---|
| Reference style | Author–year (OUP) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Antibody Therapeutics, 12(3), pp. 45–58.
Formats any DOI in the closest standard style — Antibody Therapeutics has no published style definition, so this is an approximation. No sign-up. |
| Publishes research in | Monoclonal and Polyclonal Antibodies Research CAR-T cell therapy research Protein purification and stability HER2/EGFR in Cancer Research SARS-CoV-2 and COVID-19 Research |
| ISSN | 2516-4236 |
| Citation impact (2-yr) | 2.95 |
| h-index | 33 |
| i10-index | 81 |
| Total citations | 3,660 |
| Article processing charge | $2,146 |
| Open access | Yes |
| Top institutions publishing here | National Cancer Institute |
| Journal website | academic.oup.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Antibody therapies have become an important class of therapeutics in recent years as they have exhibited outstanding efficacy and safety in the treatment of several major diseases including cancers, immune-related diseases, infectious disease and hematological disease. There has been significant progress in the global research and development landscape of antibody therapies in the past decade.…
Trastuzumab, an epidermal growth factor receptor 2 (HER2) targeting humanized monoclonal antibody, has been approved for the treatment HER2-positive breast cancer and HER2-positve metastatic gastric cancer. However, cardiotoxicity associated with its clinical application poses challenges for clinicians and patients, mechanisms of which are still evolving. This review will summarize the current mechanistic understanding of trastuzumab-mediated…
The targeting of surface antigens expressed on tumor cells by monoclonal antibodies (mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This review will summarize the process of ADCC, its important role in the efficacy of mAb therapy, how…
Thirty four (34) of the total US FDA approved 103 therapeutic antibody drugs, accounts for one third of the total approved mAbs, are formulated with high protein concentration (100 mg/mL or above) which are the focus of this article. The highest protein concentration of these approved mAbs is 200 mg/mL. The dominant administration route is…
The macrophage checkpoint is an anti-phagocytic interaction between signal regulatory protein alpha (SIRPα) on a macrophage and CD47 on all types of cells - ranging from blood cells to cancer cells. This interaction has emerged over the last decade as a potential co-target in cancer when combined with other anti-cancer agents, with antibodies against CD47…
